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Abstract
According to the “monoclonal hypothesis” of atherosclerosis, several studies suggest that cancer and atherosclerosis may
have several fundamental biological mechanisms in common. Therefore, an increase in the mutation rate may be involved in
the pathogenesis of atherosclerotic plaques.
The aim of the study was to verify the presence of chromosomal damage in peripheral blood lymphocytes in patients with
coronary artery disease by using micronucleus (MN) test, a reliable biomarker in genetic and cancer risk assessment.
Subjects included 53 patients with documented coronary ischemic heart disease (group I); 10 patients with valvular heart
disease in absence of atherosclerotic lesions of the coronary arteries (group II) and 16 healthy subjects, age- and sex-matched
(group III) were studied as controls. For each subject, two separate cultures were performed and 1000 binucleated cells were
scored for the evaluation of MN frequency.
The mean (±S.E.M.) of MN frequency were 11.9±1.7, 5.9±1.2 and 3.6±0.7 in groups I, II and III, respectively. The MN
frequency of group I was significantly higher than that of group III (P = 0.02). In group I, MN frequency increased with the
number of affected vessels (6.3± 0.7, 13.9± 1.6, 14.9± 5.3 for one-, two-, and three-vessel disease, respectively). Scheffe’s
test showed that MN frequency was significantly higher in two-vessel compared with one-vessel disease (P = 0.0077).
Moreover, a positive relationship was found between MN levels and the severity of the disease, calculated by the Duke
scoring system (R = 0.28, P = 0.032), as well as the systolic blood pressure (R = 0.34, P = 0.009).
These results suggest that coronary artery disease in humans is a condition characterized by an increase of DNA damage,
positively correlated with the severity of the atherosclerotic disease. © 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
In recent years, considerable advances have been
made in the understanding of molecular alterations
and genetic determinants in the cardiovascular disease.
Recent studies suggest the presence, in atherosclerotic
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tissues, of specific molecular DNA alterations which
may be involved in the development and/or progres-
sion of the disease.
The most prevalent hypothesis concerning the
pathophysiological mechanisms of atherosclerotic
plaque formation is the “inflammatory response to
injury” [1], which states that proliferation of smooth
muscle cells is an inflammation-fibroproliferative
reaction to different insults to the arterial wall. In-
deed, the discovery that the cells of an atherosclerotic
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plaque are monotypic, led to the proposal of an alter-
native hypothesis — the “monoclonal hypothesis” [2].
This theory proposes that atherosclerosis begins as a
mutation or viral hit, transforming a single, isolated
smooth muscle cell into the progenitor of a prolifera-
tive clone in the same manner as a benign tumor.
According to this hypothesis, plaques and tumors
may share important pathogenic features including
the occurrence of one or more mutational events
[3–8]. At present, plaque monoclonality is a con-
firmed observation [9,10], but evidence of clonality
does not necessarily have etiological or pathophys-
iological significance. Nevertheless, some evidence
has been reported that identifies and quantifies the
involvement of somatic mutations in ischemic heart
disease. Moreover, much discussion has arisen about
the carcinogenicity of cardiovascular drugs, includ-
ing diuretics, beta-blockers, calcium antagonists and
ACE-inhibitors [11]. Therefore, the issue is so sensi-
tive that an approach through laboratory endpoints of
genotoxicity may be worthwhile.
To make a further leap in knowledge, it is nece-
ssary to employ studies of mutations in cells from
atherosclerotic tissue to verify the presence of specific
genetic changes in cells of patients with documented
atherosclerosis.
Therefore, in order to investigate the presence
of genetic damage in patients with coronary artery
Table 1
Demographic and clinical characteristics of the patients and controls
Coronary artery
disease (n = 53)
Valvular heart
disease (n = 10)
Healthy control
subjects (n = 16)
Age (years) 64.9 ± 1.5 58.5 ± 7.2 60.7 ± 2.0
Gender (n)
Men 45 8 10
Women 8 2 6
Smoking habit (n)
Smokers 10 2 4
No smokers 5 2 2
Ex-smokers 38 6 10
Hypertensives (n) 50 6 0
Diabetes (n) 11 2 0
Drug therapy (n)
Nitrates 42 0 0
Aspirin 43 2 0
ACE-inhibitors 22 3 0
Calcium-channel blockers 29 2 0
disease (CAD), we performed a cytogenetic moni-
toring study employing the micronucleus (MN) test,
a sensitive and reliable system for the evaluation of
spontaneous and mutagen-induced DNA damage in
human peripheral blood lymphocytes [12].
2. Materials and methods
2.1. Study population
Three groups of patients were prospectively stud-
ied. Group I consisted of 53 patients, recruited from
our hospital, with clinical evidence of coronary artery
disease as defined by clinical presentation (angina
pectoris and/or myocardial infarction) and angio-
graphic documentation of CAD. Group II consisted
of 10 patients admitted to our hospital with a diag-
nosis of valvular heart disease in which angiographic
examination excluded the presence of CAD. No pa-
tients were receiving antioxidant therapy. The medi-
cations used by patients included nitrates, oral aspirin,
calcium-channel blockers and ACE-inhibitors. Clin-
ical and demographic characteristics of patients and
controls are reported in Table 1. Group III included
16 healthy control subjects matched with the patients
for age, sex and smoking habits. Each subject was
interviewed concerning smoking status, occupational
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exposure to potential carcinogens and mutagens, and
dietary history. Smokers were classified as individuals
who smoked at least three cigarettes per day at the
time of analysis; ex-smokers had quit smoking for at
least 6 months and non smokers were individuals who
had never smoked. Individuals who smoked less than
three cigarettes per day were not included in the study.
Informed consent was obtained from all patients and
control subjects according to our ethical committee.
Venous blood samples were taken before angiographic
procedure to exclude the effects of X-ray exposure.
2.2. Angiographic study
All patients underwent coronary angiography;
coronary stenosis was considered significant in the
presence of a luminal diameter narrowing of ≥50%.
The severity of CAD was expressed simply by the
number of affected vessels (one-, two-, or three-vessel
disease). Moreover, the extent and the severity of
CAD was also evaluated by means of the Duke scor-
ing system [13]. This CAD prognostic index considers
the number of the diseased major vessels (one-, two-,
and three-vessel, as well as left main coronary artery
disease), the percent narrowing of the major vessels,
and involvement of the left anterior descending coro-
nary artery, particularly when the proximal segment
shows a severe stenosis (≥95%). The Duke score
ranges from 0 to 100 grade scale (0 = no disease,
100 = most severe disease).
2.3. Lymphocyte preparation and MN assay
Peripheral blood was collected using heparin as
an anticoagulant. Cellular cultures from each sub-
ject were set up by mixing 0.3 ml of whole blood
with 4.7 ml of RPMI 1640 medium (GIBCO), sup-
plemented with 10% fetal calf serum (GIBCO), 1.5%
phytohemagglutin (PHA, GIBCO) and antibiotics
(penicillin 100 IU/ml and streptomycin 100 mg/ml,
Sigma, St. Louis, MO, USA). All cultures were in-
cubated at 37◦C in a humidified atmosphere of 5%
CO2 and 95% O2. For evaluation of MN frequency,
cells were blocked in cytokinesis by adding, after
44 h, cytochalasin B (6g/ml final concentration,
Sigma). Cell cultures were then harvested after 72 h.
Harvesting of cells, hypotonic treatment, fixation
and slide preparation were performed according to
standard methods [14,15]; fixed cells were dropped
onto clean microscopic slides, air dried and stained
by the Giemsa technique.
2.4. Slide scoring
For each sample, 1000 binucleated cells were scored
blindly under the optical microscope (final magnifica-
tion 400×) for MN analysis, following the criteria for
MN acceptance listed by Fenech [16]. MN frequency
was expressed as the number of micronucleated
binucleated cells (MNBN), containing one or more
MN per 1000 cells.
2.5. Statistical analysis
The results were expressed as mean ± S.E.M. The
data for the three independent groups (I, II and III)
were analyzed by ANOVA analysis and the significant
differences among a group of means were tested by
the Scheffe’s test. The Scheffe’s test was chosen for
multiple comparisons because it is generally consid-
ered to be one of the most conservative tests and also
because it is very robust to violations of the assump-
tions typically associated with the multiple compar-
isons procedure (including heterogeneous variances).
Because MN values are not normally distributed,
the logarithmic transformation of original data was
used for statistical analysis in order to normalize the
distribution values. Multiple regression analysis was
applied to investigate the effect of each variable (age,
gender, smoking status, Duke score, systolic blood
pressure, dyslipidemia, drug number) in determining
MN frequency. The statistical analyses were per-
formed using the statistical package Statview 5.0.1
(SAS Institute).
3. Results
The mean (±S.E.M.) MN frequencies were 11.9±
1.7, 5.9 ± 1.2 and 3.6 ± 0.7 in groups I, II and III,
respectively. The mean MN frequency of group I was
significantly higher than that of group III (P = 0.02).
No significant differences were present between group
I and group II (P = 0.29), or between group II and
group III (P = 0.88).
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Fig. 1. Mean MN frequencies in patients with one-vessel disease (n = 16), two-vessel disease (n = 22), three-vessel disease (n = 15) and
valvular heart disease (n = 10).
One-, two- and three-vessel disease were observed
in 16, 22, and 15 patients, respectively. As shown in
Fig. 1, the mean MN frequency increases with the
number of affected vessels (6.3 ± 0.7, 13.9 ± 1.6,
14.9 ± 5.3 for one-, two-, and three-vessel disease,
respectively). Scheffe’s test showed that the MN
frequency was significantly higher in two-vessel com-
pared with one-vessel disease (P = 0.0077). For each
CAD patient the extent of coronary artery disease,
expressed as Duke score, is reported in Table 2, in
which the patients are listed according to the number
of diseased vessels and the Duke score itself.
Multiple regression analysis showed that Duke
score and systolic blood pressure appeared to be the
only two independent determinant factors in determin-
ing MN frequency in our cardiovascular population
(Table 3). The relationship between MN frequency
and Duke score as well as systolic blood pressure is
shown in Fig. 2.
4. Discussion
To the best of our knowledge, this study is the
first cytogenetic monitoring in human lymphocytes of
patients with CAD.
The evidence for a monoclonal origin of human
atherosclerotic plaques has emphasized the need to
consider the development of atherosclerotic disease as
a formation of a benign tumor [2]. In this hypothesis
the plaques may be a result of a clonal growth of
the smooth muscle cells, in response to a mutational
event [3–8]. Indeed, epidemiological studies indicate
that some mutagenic agents may exert carcinogenic as
well as atherogenic effects [17–23].
4.1. Comparison with previous studies
Recent studies suggest that DNA alterations are
present in atherosclerotic tissues and can play a funda-
mental role in the pathogenesis of this disease. Indeed,
DNA samples extracted from smooth muscle cells of
atherosclerotic lesions possess transforming capabil-
ity [24,25]. This evidence, together with the discovery
of microsatellite instability in human atherosclerotic
lesions [26–28], suggests the hypothesis that genomic
destabilization can result in the misregulation of the
cells harboring these mutations and may play a pivotal
role in the formation of atherosclerotic plaque.
In addition, cytogenetic studies of human plaque
smooth muscle cells have revealed the presence
of a variety of karyotipic abnormalities, primarily
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Table 2
Severity of CAD by Duke score [13]a
Patients Vessels involved Duke score
1 1-VD (50%) 19
2 1-VD (50%) 19
3 1-VD (50%) 19
4 1-VD (50%) 19
5 1-VD (75%) 23
6 1-VD (75%) 23
7 1-VD (95%) 32
8 1-VD (95%) 32
9 1-VD (95%) 32
10 1-VD (95%) 32
11 1-VD (95%) 32
12 1-VD (95%) 32
13 1-VD (95%) 32
14 1-VD (95%) 32
15 1-VD (prox LAD 95%) 48
16 1-VD (prox LAD 95%) 48
17 2-VD (75%, 50%) 37
18 2-VD (75%, 50%) 37
19 2-VD (75%, 50%) 37
20 2-VD (75%, 75%) 37
21 2-VD (75%, 75%) 37
22 2-VD (75%, 75%) 37
23 2-VD (75%, 75%) 37
24 2-VD (75%, 75%) 37
25 2-VD (95%, 50%) 37
26 2-VD (95%, 50%) 37
27 2 VD (95%, 75%) 37
28 2-VD (95%, 95%) 42
29 2-VD (95%, 95%) 42
30 2-VD (LAD 95%, 50%) 48
31 2-VD (LAD 95%, 75%) 48
32 2-VD (LAD 95%, 75%) 48
33 2-VD (LAD 95%, 95%) 48
34 2-VD (LAD 95%, 95%) 48
35 2-VD (LAD 95%, 95%) 48
36 2-VD (LAD 95%, 95%) 48
37 2-VD (prox LAD 95%, 95%) 56
38 2-VD (prox LAD 95%, 95%) 56
39 3-VD (75%, 75%, 50%) 56
40 3-VD (95%, 50%, 50%) 63
41 3-VD (95%, 75%, 75%) 63
42 3-VD (95%, 75%, 75%) 63
43 3-VD (95%, 75%, 75%) 63
44 3-VD (95%, 95%, 50%) 63
45 3-VD (95%, 95%, 50%) 63
46 3-VD (95%, 95%, 75%) 63
47 3-VD (95%, 95%, 75%) 63
48 3-VD (prox LAD 50%, 95%, 75%) 67
49 3-VD (prox LAD 50%, 95%, 75%) 67
50 3-VD (prox LAD 50%, 95%, 75%) 67
51 3-VD (prox LAD 95%, 95%, 95%) 74
52 3-VD (prox LAD 95%, 95%, 95%) 74
53 3-VD (left main coronary
artery disease, 75%, 95%)
82
a 1-, 2-, and 3-VD: one-, two- and three-vessel disease; prox:
proximal; LAD: left anterior descending coronary artery.
Table 3
Multiple regression between MN frequency and risk factors
Variable Regression
coefficients
Significance
(P)
Gender −0.122 0.374
Age 0.011 0.934
Smoking 0.034 0.806
Dyslipidemia 0.104 0.419
Duke score 0.265 0.058
Systolic blood pressure 0.308 0.022
Drug therapy 0.005 0.970
involving aneuploidies [29–31]. Moreover, elevated
levels of aneuploidy cells were found in aortic en-
dothelial cells of elderly subjects, as well as those of
patients with atherosclerosis [32].
In view of this evidence, since MN can contain
a fragment or a whole chromosome, it would be of
interest to verify the presence of centromeric DNA in
MN, by application of fluorescence in situ hybridiza-
tion (FISH) with alphoid satellite probe [33]. These
approaches will permit us to determine whether so-
matic cells of patients with CAD show a constitutional
predisposition to aneuploidy.
4.2. Value and limitation of the study
Our study provides evidence for the existence of
an association between micronucleus frequency and
the severity of coronary artery disease. The biological
plausibility suggested by several authors [34–36] and
the good agreement with the study reporting higher
DNA adduct levels in cardiac tissue of patients with
severe coronary artery disease [22] further strengthen
our findings. It is worth noting that the relationship
between DNA damage and increased systolic blood
pressure generally agrees with several studies doc-
umenting the association between cancer mortality
and hypertension [37,38], thus strongly suggesting
the presence of possible common pathophysiological
mechanisms between cancer and hypertension [35].
On the other hand, it is well known that DNA dam-
age frequently occurs in cells exposed to oxidative
stress [39], and ischemic heart disease is an ideal ex-
ample of increased production of oxygen free radicals
[40]. In addition, recent studies showed an elevated
micronucleus frequency positively correlated with
plasma homocysteine [41,42], which is considered to
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Fig. 2. Simple regression analysis between MN frequency: (a) Duke score; (b) Systolic blood pressure.
be an important risk factor for cardiovascular disease
[43].
However, some limitations of this study should also
be considered. First and foremost, the possibility that
drug therapies could be responsible for the increased
micronucleus rate should be considered, even though
we have previously observed that long-term calcium
antagonist therapy is not associated with an increased
incidence of chromosome aberrations in human lym-
phocytes [44]. On the contrary, it has been recently
suggested that nitric oxide and nitrate therapy could
show a potential genotoxic activity [45,46]. These
limitations encourage additional work in this area. We
observed a clear relationship between increased MN
frequencies and the severity of coronary artery disease;
however, more direct experimental data are needed at
this point to evidence DNA damage accumulation in
ischemic heart disease and, particularly, to investigate
whether the drugs given to treat CAD are potentially
mutagenic. Moreover, further studies might include
measures of folate, B12 and homocysteine which are
risk factors for cardiovascular disease as well as mi-
cronucleus frequency. Finally, it will be interesting
to determine whether somatic mutations or genetic
changes are present in the smooth muscle cells of the
atherosclerotic plaque leading to the development of
the lesion or plaque instability.
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